Pharmacia Ab

Active Biotech Ab

Per Axel Bj&ouml;rk

Tomas Fex

Mikael Dohlsten

Terje Kalland

Per Antonsson

Johan Hansson

Lars Abrahms&eacute;n

Dorthe Da Gra&ccedil;a Thrige

G&ouml;ran Forsberg

Lars Olof G&ouml;ran Pettersson

Pous S&oslash;rensen

The present invention relates to a novel heterocyclic compound, a pharmaceutical composition comprisining said compound, a method and use of said compound for clinical treatment of medical conditions which may benefit from immunomodulation, e.g. rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28. A method of screening compounds for their ability of inhibiting ligand-induced co-stimulatory receptor internalization pathways in immune competent human cells is described. Said immune competent human cells are incubated at conditions capable of inducing co-stimulatory receptor internalization in the presence of at least one test compound and the suppression of the ligand-induced co-stimulatory receptor internalization determined. There is also described a kit for use in such a method, as well as an immunoregulatory drug capable of blocking down-modulation of a ligand-induced receptor.

Immunomodulating compounds

Modified/chimeric superantigens and their use

Growing community of inventors

Helsingborg, Sweden

Per Axel Björk

Growing community of inventors

Helsingborg, Sweden

Per Axel Bj&ouml;rk

Per Axel Björk